Skip to main content

Table 1 Baseline characteristics of included patients and clinical characteristics and biological differences between the 2 classes

From: Physiological and clinical variables identify ARDS classes and therapeutic heterogeneity to glucocorticoids: a retrospective study

Baseline Characteristic

All patients (n = 1104)

Class1 (n = 866)

Class2 (n = 238)

P value

Age, year

63 ± 18

64 ± 18

61 ± 18

0.0258

Gender, n (%)

   

0.14

 female

501(45.4%)

403(46.54%)

98(41.18%)

 

 male

603(54.6%)

463(53.46%)

140(58.82%)

 

Height, cm

168.8 ± 10

168.7 ± 10

169.0 ± 10

0.6295

Weight, kg

85.8 ± 24

85.4 ± 24

87.3 ± 24

0.2809

The risk of ARDS, n (%)

   

< 0.001

 pneumonia

319(28.9%)

240(27.71%)

79(33.19%)

 

 trauma

378(34.2%)

203(23.44%)

52(21.85%)

 

 sepsis

247(22.4%)

87(10.05%)

49(20.59%)

 

 aspiration

14(1.3%)

9(1.04%)

3(1.26%)

 

 other

382(34.6%)

327(37.76%)

55(23.11%)

 

Vasopressor Use, n (%)

    

 vaso_use_24h#1

119(10.8%)

44(5.08%)

75(31.51%)

< 0.001

 vaso_use_48h#2

150(13.6%)

64(7.39%)

86(36.13%)

< 0.001

 vaso_use_all#3

217(19.7%)

116(13.39%)

101(42.44%)

< 0.001

Corticosteroids, n (%)

172(15.6%)

125(14.13%)

47(19.75%)

0.045

Race, n (%)

   

0.009

 White

696(63.04%)

568(65.59%)

128(53.78%)

 

 BLACK/AFRICAN

75(6.79%)

53(6.12%)

22(9.24%)

 

 HISPANIC/LATINO

45(4.08%)

31(3.58%)

14(5.88%)

 

 Asian

29(2.63)

24(2.77%)

5(2.10%)

 

 other

259(23.46%)

190(21.94%)

69(28.99%)

 

PaO2fiO2ratio

161.8(98.9-246.8)

175(115–263)

113(75–193)

< 0.0001

PcO2, mmHg

49(43–56)

49(43–55)

52(44–60)

0.0039

PO2, mmHg

80(66–108)

81(68–113)

74(61–90)

< 0.0001

Aado2, mmHg

356.2(216.0-528.6)

324(205–492)

503(293–577)

< 0.0001

Totalco2, mEq/L

21(18–24)

22(20–25)

16(14–18)

< 0.0001

 min volume, L/min

11.5 ± 3

11.1 ± 3

12.8 ± 3

< 0.0001

Tidal volume, mL

410(345.5-482.5)

410(341–480)

419(351–490)

0.2167

Plateau pressure, cmH2O

22(18–26)

21(18–25)

26(21–30)

< 0.0001

Peep, cm H2O

8(5–11)

7(5–10)

10(6–15)

< 0.0001

FiO2, %

100(60–100)

100(60–100)

100(100–100)

< 0.0001

Lactate, mg/dl

3(1.7–4.9)

2.6(1.6–3.9)

6.4(4.1–8.7)

< 0.0001

Be, mmol/L

-5(-8–1)

-3(-6-0)

-12(-15–9)

< 0.0001

Hematocrit, %

35.7 ± 6

35.4 ± 6

36.8 ± 7

0.0018

Hemoglobin, mg/dL

9.7 ± 2

9.9 ± 2

9.1 ± 2

< 0.0001

Platelets, 109/L

155.5(103–216)

169(114–226)

117(73–172)

< 0.0001

Wbc, 109/L

14.9(11.2–20.0)

14.1(10.9–18.8)

17.6(12.7–23.3)

< 0.0001

Glucose, mg/dL

179(146–223)

171(142–207)

233(181–301)

< 0.0001

AG, mmol/L

16(13–19)

15(13–17)

21(18–24)

< 0.0001

Bicarbonate, mmol/L

21 ± 4

22 ± 4

16 ± 4

< 0.0001

Bun, mmol/L

21(15–30)

19(14–26)

31(20–46)

< 0.0001

Calcium, mg/dL

7.9 ± 0.9

8.0 ± 0.8

7.5 ± 1.0

< 0.0001

Chloride, mmol/L

108(105–112)

108(105–111)

110(105–113)

< 0.0001

Creatinine, mg/dL

1.1(0.8–1.6)

1.0(0.8–1.3)

1.8(1.3–2.7)

< 0.0001

Sodium, mmol/L

141 ± 4

140 ± 4

142 ± 5

0.0005

Potassium, mmol/L

3.9 ± 0.5

3.9 ± 0.5

3.9 ± 0.6

0.4217

 h, beats per min

108(93–123)

105(91–119)

120(105–135)

< 0.0001

Temperature, °C

37.7 ± 0.8

37.7 ± 0.8

37.7 ± 0.8

0.6690

Sbp, mmHg

85 ± 14

87 ± 14

80 ± 14

< 0.0001

RR, breaths per min

27(24–32)

27(23–31)

29(25–34)

< 0.0001

Urine output, L

1.5(0.9–2.3)

1.6(1-2.4)

1.0(0.5–1.8)

< 0.0001

Scoring systems

    

 SAPSII

41(33–51)

39(31–48)

49(40–62)

< 0.0001

 SOFA

8(5–11)

7(5–9)

12(10–14)

< 0.0001

  1. Abbreviations defined: Aado2 = alveolar-arterial oxygen difference; PEEP = positive end-expiratory pressure; Be = residual base; AG = aniongap; Bun = urea nitrogen; HR = heart rate; RR = respiratory rate; Sbp = systolic blood pressure. Normally distributed data are expressed as mean ± standard deviation; non-normally distributed data are expressed as median (interquartile range); categorical data are expressed as n (%). p-values represent t-test for normally distributed data, Wilcoxon’s rank test for non-normally distributed data, and chi-square test for categorical variables. vaso_use_24h#1: patients who received vasopressor medications within the first 24 hours of admission to the ICU. vaso_use_48h#2: patients who received vasopressor medications within the first 48 hours of admission to the ICU. vaso_use_all#3: patients who received vasopressor medications at any time during ICU.